SCHEDULE: Millennium Management's Indivior Stake Drops Below 5%

Millennium Management LLC and affiliates reported their beneficial ownership in Indivior Pharmaceuticals, Inc. common stock has fallen to 3.8%, ceasing to be a 5% beneficial owner.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively filed a Schedule 13G.
• The reporting persons beneficially own 4,806,556 shares of Indivior Pharmaceuticals, Inc. Common Stock, representing 3.8% of the class.
• They ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing, after having acquired beneficial ownership of more than 5% on March 17, 2026.
• The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Israel A. Englander.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral compliance filing. It discloses a change in beneficial ownership by a significant institutional investor, but the ownership is now below the 5% threshold, indicating a passive stance.

Positives

• The reporting persons are in full compliance with SEC regulations by disclosing their updated beneficial ownership.

Negatives

• The beneficial ownership of Indivior Pharmaceuticals, Inc. common stock by Millennium Management LLC and its affiliates has decreased to 3.8%, falling below the 5% threshold previously held.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Indivior Pharmaceuticals, Inc.'s future performance or operations.

Management Comments

• We certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Indivior Pharmaceuticals, Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors. Millennium Management is a prominent hedge fund, and its stake in a pharmaceutical company like Indivior indicates its investment interest in the sector, though the current filing shows a reduction below the 5% threshold, signifying a passive investment stance.

Stakeholder Impact

• Shareholders of Indivior Pharmaceuticals, Inc. are informed about the updated beneficial ownership of a significant institutional investor.

Key Dates

Keywords

Indivior Pharmaceuticals, Millennium Management, Schedule 13G, beneficial ownership, common stock, institutional investor, Israel A. Englander